List cleansing
Fleur Anderson MP (Lab, Putney) first asked what steps the Government are taking to improve access to GPs, then followed up asking about the impact of the FP69 list cleansing process in London, saying:
“I am concerned about NHS England’s GP list cleaning programme and its impact on London specifically. Putney GPs have told me that in the last six months, 344,000 patients have been taken off GP lists, 44% of whom are in London. Some are taken off after not responding to a single letter. That means that they do not get cancer check-ups, vaccines or GP care. Something is going on with the London part of the GP lists. Will the Minister pause, review the programme, look into it and meet me and other London MPs to talk about it?”
Dame Diana Johnson, the Primary Care Minister, replied:
“I understand the concerns that my hon. Friend has raised, particularly with regard to vulnerable patients, but it is important that GP lists are as accurate as possible. We think that there are around 6 million more registrations than England’s population and most people flagged are confirmed to have moved Toggle showing location ofColumn 948abroad. Strong safeguards are in place, including no patient being removed on the basis of a single indicator or because they failed to respond to one piece of correspondence. Overall, it takes more than five months from identifying a patient who may no longer reside to deregistering them from a practice system. I am always happy to meet my hon. friend.”
Continuity of care
Former Health Secretary Jeremy Hunt (Con, Godalming and Ash) asked what plans the Government has to improve continuity of care in the NHS, then followed up by asking about evidence that it improved health outcomes in a Norwegian study, specifically:
“Has the Minister read the Norwegian population study published in the British Journal of General Practice, which says that people who see the same doctor over many years are 30% less likely to need out-of-hours care, 28% less likely to need emergency care and 25% less likely to die? It has been two years since the Government made the pledge to bring back the family doctor, but the basic structure of general practice has not changed. Can we see some changes in the next GP contract negotiations to bring back the system we used to have, in which everyone has their own doctor?”
Dame Diana Johnson’s responded:
“One of the reasons the Government committed to bring back the family doctor was the importance of maintaining continuity of care for patients. I am pleased to say that the proportion of patients who say they are able to see their preferred clinician when they make a GP appointment has risen from 61% to 68% since the election, but we recognise that there is more to do, and this remains an important priority for the Government.”
“I recognise the enormous experience and knowledge of the former Secretary of State for Health and his work on this issue and patient safety more generally. The Department has started to look at expert advice, with a clinical working group, on how best to support continuity of care in modern general practice. I have not read the report that he referred to, but I am happy to go and have a look it. I am also happy to have a discussion with him, because it would be helpful to understand his thinking on what I know he considers to be a very important issue.”
Drug shortages
Rachel Blake (Lab, Cities of London and Westminster) asked about the cannabis-derived drug Bedrolite, whose manufacturer has gone bankrupt:
“I am grateful that the Department has moved swiftly to identify the issues with the supply of Bedrolite from Bedrocan, the company in real difficulty in the Netherlands. I understand that there is confidence in supplies until 2027, but my constituents say that that may depend on whether someone has an NHS or a private prescription. Would the Minister and his officials meet me to go through these processes, some of which, from my constituents’ experience, have been very bureaucratic?”
James Frith, the Health Innovation Minister replied:
“My hon. friend makes a really important point. Ensuring sustainable supply for so sensitive a medicine to address epilepsy is uppermost in my mind. It is a live situation, I am working at pace with officials, and I will update her accordingly.”